Alopecia Universalis in a Multiple Sclerosis Patient After Switching From Rituximab to Ocrelizumab: A Case Report

被引：0
|
作者：
Mahyad, Mahshid [1 ]
Baghaei, Mahdieh [2 ]
Baghaei, Ava [1 ]
Nahayati, Mohammadali [1 ]
机构：
[1] Mashhad Univ Med Sci, Fac Med, Dept Neurol, Mashhad, Iran
[2] Mashhad Univ Med Sci, Fac Med, Dept Radiol, Mashhad, Iran
来源：
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | 2024年 / 27卷 / 12期
关键词：
alopecia areata; alopecia universalis; multiple sclerosis; ocrelizumab; rituximab; MONOCLONAL-ANTIBODY; PLACEBO; DEPLETION;
D O I：
10.1111/1756-185X.70028
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Ocrelizumab is a humanized monoclonal antibody, which acts as an anti-CD20 antibody. It is used as a treatment of both relapsing-remitting multiple sclerosis (RRMS) and Progressive types. The aim of this study is to report the first patient with alopecia universalis after switching from rituximab to ocrelizumab. A 37-year-old woman with a history of SPMS, diagnosed 8 years ago, used to be treated with rituximab. Her drug was switched to ocrelizumab from 6 months ago. She presented with patchy scalp hair loss a day after receiving the second dose of ocrelizumab. Her hair loss rapidly progressed in 3-4 days to total body hair loss in a patchy pattern. Ocrelizumab may be responsible for autoimmune reactions such as alopecia universalis in immunocompromised patients.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Management of Fulminant Multiple Sclerosis With Rituximab A Case Report
    Parfenov, Valeriy
    Du Pasquier, Renaud
    Schluep, Myriam
    NEUROLOGIST, 2015, 19 (06) : 155 - 157
  • [22] Babesia microti infection in a patient with multiple sclerosis treated with ocrelizumab
    Haberli, Nicholas
    Coban, Hamza
    Padam, Charanpreet
    Montezuma-Rusca, Jairo M.
    Creed, Marina A.
    Imitola, Jaime
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 48
  • [23] Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis
    Nygaard, Gro Owren
    Torgauten, Hilde
    Skattebol, Lars
    Hogestol, Einar August
    Sowa, Piotr
    Myhr, Kjell-Morten
    Torkildsen, Oivind
    Celius, Elisabeth Gulowsen
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 62
  • [24] Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No
    Wallin, Mitchell T.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (09) : 1159 - 1161
  • [25] Improvement of Atopic Dermatitis and Alopecia Universalis with Dupilumab: a case report
    Alotaibi, Lama
    Alfawzan, Abdulrahman
    Alharthi, Raghad
    Al Sheikh, Afaf
    DERMATOLOGY REPORTS, 2022, 14 (02)
  • [26] Dengue fever in a multiple sclerosis patient taking Ocrelizumab
    Guerra, Tommaso
    Bollo, Luca
    Trojano, Maria
    Iaffaldano, Pietro
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (13) : 2116 - 2118
  • [27] Viral pericarditis following ocrelizumab in a multiple sclerosis patient
    Giuseppina Miele
    Gianmarco Abbadessa
    Elisabetta Maida
    Simona Bonavita
    Neurological Sciences, 2023, 44 : 2947 - 2949
  • [28] Viral pericarditis following ocrelizumab in a multiple sclerosis patient
    Miele, Giuseppina
    Abbadessa, Gianmarco
    Maida, Elisabetta
    Bonavita, Simona
    NEUROLOGICAL SCIENCES, 2023, 44 (08) : 2947 - 2949
  • [29] NK Cell Levels Correlate with Disease Activity in Patients with Multiple Sclerosis on Ocrelizumab/Rituximab Therapy
    Dal Bello, Simone
    Lorenzut, Simone
    Saccomano, Emma
    Tereshko, Yan
    Gigli, Gian Luigi
    Pucillo, Carlo Ennio
    Valente, Mariarosaria
    PHARMACEUTICALS, 2024, 17 (02)
  • [30] Alopecia Universalis Occurring after Alemtuzumab Treatment for Multiple Sclerosis. A Two-Year Follow-Up of Two Patients
    Borriello, Giovanna
    Ianniello, Antonio
    Toosy, Ahmed T.
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (14)
12345